- Investing Ideas
- Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Results
4
Companies which are potentially undervalued and in an acceptable financial position.
4 companies
Tecan Group
Market Cap: CHF 1.6b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 124.20
7D
-10.0%
1Y
-17.9%
Roche Holding
Market Cap: CHF 257.2b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROP
CHF 322.00
7D
0.6%
1Y
22.9%
Novartis
Market Cap: CHF 217.0b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 113.70
7D
-4.3%
1Y
22.9%
Siegfried Holding
Market Cap: CHF 3.4b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 78.05
7D
-7.1%
1Y
-16.1%